PMID- 18205840
OWN - NLM
STAT- MEDLINE
DCOM- 20090114
LR  - 20141120
IS  - 1751-5521 (Print)
IS  - 1751-5521 (Linking)
VI  - 30
IP  - 5
DP  - 2008 Oct
TI  - The biological characteristics of dendritic cells derived in vitro from 
      myelogeneous leukemia cells and healthy donor cells.
PG  - 372-81
LID - 10.1111/j.1751-553X.2007.00986.x [doi]
AB  - Successful adoptive immunotherapy for leukemia depends on the generation of T 
      cells that can specifically react with malignant cells. Dendritic cells (DCs) are 
      important antigen-presenting cells in the development of antileukemia T-cell 
      responses. Mononuclear cells (MNC) were isolated from peripheral blood or bone 
      marrow of patients with chronic myelogenous leukemia (CML), and acute myelogenous 
      leukemia (AML). After incubation with granulocyte-macrophage colony-stimulating 
      factor, interleukin (IL)-4, and tumor necrosis factor-alpha, MNC developed 
      morphological characteristics of DCs in vitro, which were confirmed by phenotypic 
      assay. Fluorescence in situ hybridization demonstrated the presence of fusion 
      gene in the nuclei of representative CML or AML-M3 samples, indicating that the 
      cells were leukemic in origin. IL-12 levels were significantly higher in AML-DCs 
      and CML-DCs prestimulated with phorbol 12-myristate 13-acetate than in the 
      corresponding leukemic cells, but were lower than that of healthy donors. These 
      cells were potent stimulators of lymphocyte proliferation in specific in vitro 
      assays for DC function. However, the stimulatory abilities of allogeneic T cells 
      in a mixed lymphocyte reaction were impaired compared with those of mature DCs 
      derived from healthy donors, although T-cell stimulatory effects were 
      significantly increased in these differentiated leukemia-DCs. These results 
      suggest that functional DCs may be derived from leukemic (AML, CML) blasts in a 
      significant number of patients and may be capable of inducing leukemia-specific 
      immune responses with potentially clinically beneficial effects.
FAU - Tong, X M
AU  - Tong XM
AD  - Institute of Hematologic Disease, Department of Hematology, First Affliated 
      Hospital, Medical School, Zhejiang University, Hangzhou, China.
FAU - Yao, H P
AU  - Yao HP
FAU - Qian, W B
AU  - Qian WB
FAU - Zhu, L F
AU  - Zhu LF
FAU - Fu, Z H
AU  - Fu ZH
FAU - Huang, Z L
AU  - Huang ZL
FAU - Jin, J
AU  - Jin J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080118
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
SB  - IM
MH  - Cell Differentiation/*immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology
MH  - Flow Cytometry
MH  - Humans
MH  - In Vitro Techniques
MH  - Leukemia, Myeloid/*immunology/pathology
MH  - Lymphocyte Culture Test, Mixed
EDAT- 2008/01/22 09:00
MHDA- 2009/01/15 09:00
CRDT- 2008/01/22 09:00
PHST- 2008/01/22 09:00 [pubmed]
PHST- 2009/01/15 09:00 [medline]
PHST- 2008/01/22 09:00 [entrez]
AID - CLH986 [pii]
AID - 10.1111/j.1751-553X.2007.00986.x [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2008 Oct;30(5):372-81. doi: 10.1111/j.1751-553X.2007.00986.x. 
      Epub 2008 Jan 18.